DDMAC Numb To Purported Advantages Of Dental Anesthetic
This article was originally published in The Pink Sheet Daily
Executive SummaryWarning letter continues FDA's trend of citing superiority claims based on the route of administration.
You may also be interested in...
The first warning letter of the year from FDA’s Office of Prescription Drug Promotion goes to Teva for web pages and materials displayed at a medical conference that overstated the safety and efficacy of its MS drug Copaxone.